RoweP, FarleyT, PeregoudovA, et al.;IUD Research Group of the UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction. Corrigendum to “Rowe P et al. safety and efficacy in parous women of a 52-mg levonorgestrel-medicated intrauterine device: A 7-year randomized comparative study with the TCu380A”[Contraception 2016; 93: 498–506]. Contraception, 2016; 94(3):288.
4.
JensenJT, Lukkari-LaxE, SchulzeA, et al.Contraceptive efficacy and safety of the 52-mg levonorgestrel intrauterine system for up to 8 years: Findings from the Mirena Extension Trial. Am J Obstet Gynecol, 2022; 227(6):873.e1–873.e12.
5.
CreininMD, SchreiberCA, TurokDK, et al.Levonorgestrel 52 mg intrauterine system efficacy and safety through 8 years of use. Am J Obstet Gynecol, 2022; 227(6):871.e1–871.e7.
6.
ChenBA, KimbleT, HarrisLH, et al.Levonorgestrel 52-mg intrauterine device efficacy and safety after more than 8 years of use. Obstet Gynecol, 2023; 141(5):1004–1006.
7.
TiAJ, RoeAH, WhitehouseKC, et al.Effectiveness and safety of extending intrauterine device duration: A systematic review. Am J Obstet Gynecol, 2020; 223(1):24–35.e3.
8.
TealSB, TurokDK, ChenBA, et al.Five-year contraceptive efficacy and safety of a Levonorgestrel 52-mg intrauterine system. Obstet Gynecol, 2019; 133(1):63–70.
9.
GoldstuckND. The levonorgestrel-releasing intrauterine system 52 mg as a contraceptive versus a therapeutic: Essential differences and perspectives. Eur J Contracept Reprod Health Care, 2023; 28(3):177–183.
